DNB Markets – Isofol Medical: Approaching AGENT read-out
In our view, the Q1 report was a non-event, with the results broadly in line with our estimates. The company continued its dialogue with the FDA and has started analysis of the pivotal AGENT study; it reiterated that top-line data is set to be presented within 2–3 months. Overall, the company looks to have been on track in the quarter. We largely maintain our forecasts and assumptions as well as our fair value of SEK14–26.In line with expectations. The Q1 operating loss of cSEK50m was in line with our expectation, while total expenses were cSEK54m, compared to our forecast of cSEK53m. As in